Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amelubant (BIIL 284) in Active Rheumatoid Arthritis
NCT02251210Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2001
- Primary completion
- Nov 2002
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of amelubant in rheumatoid arthritis (RA), sponsored by Boehringer Ingelheim. Started May 2001; status: completed.
02
Drugs
amelubant
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02251210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251210.